JP7701453B2 - 固形腫瘍標的化骨格を有する細胞及びその使用 - Google Patents

固形腫瘍標的化骨格を有する細胞及びその使用 Download PDF

Info

Publication number
JP7701453B2
JP7701453B2 JP2023540538A JP2023540538A JP7701453B2 JP 7701453 B2 JP7701453 B2 JP 7701453B2 JP 2023540538 A JP2023540538 A JP 2023540538A JP 2023540538 A JP2023540538 A JP 2023540538A JP 7701453 B2 JP7701453 B2 JP 7701453B2
Authority
JP
Japan
Prior art keywords
cell
cells
receptor
domain
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023540538A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024515920A (ja
JP2024515920A5 (enExample
Inventor
バラメール バーラム
トン リー トム
ホスキング マーティン
ペラルタ エイゲン
チャン チア－ウェイ
Original Assignee
フェイト セラピューティクス，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フェイト セラピューティクス，インコーポレイティド filed Critical フェイト セラピューティクス，インコーポレイティド
Publication of JP2024515920A publication Critical patent/JP2024515920A/ja
Publication of JP2024515920A5 publication Critical patent/JP2024515920A5/ja
Priority to JP2025031958A priority Critical patent/JP2025105605A/ja
Application granted granted Critical
Publication of JP7701453B2 publication Critical patent/JP7701453B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/39—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by a specific adjuvant, e.g. cytokines or CpG
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023540538A 2022-04-08 2023-04-07 固形腫瘍標的化骨格を有する細胞及びその使用 Active JP7701453B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025031958A JP2025105605A (ja) 2022-04-08 2025-02-28 固形腫瘍標的化骨格を有する細胞及びその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263329364P 2022-04-08 2022-04-08
US63/329,364 2022-04-08
US202263380378P 2022-10-20 2022-10-20
US63/380,378 2022-10-20
PCT/US2023/065550 WO2023196994A1 (en) 2022-04-08 2023-04-07 Cells having solid tumor targeting backbone and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025031958A Division JP2025105605A (ja) 2022-04-08 2025-02-28 固形腫瘍標的化骨格を有する細胞及びその使用

Publications (3)

Publication Number Publication Date
JP2024515920A JP2024515920A (ja) 2024-04-11
JP2024515920A5 JP2024515920A5 (enExample) 2024-08-15
JP7701453B2 true JP7701453B2 (ja) 2025-07-01

Family

ID=88243835

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023540538A Active JP7701453B2 (ja) 2022-04-08 2023-04-07 固形腫瘍標的化骨格を有する細胞及びその使用
JP2025031958A Pending JP2025105605A (ja) 2022-04-08 2025-02-28 固形腫瘍標的化骨格を有する細胞及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025031958A Pending JP2025105605A (ja) 2022-04-08 2025-02-28 固形腫瘍標的化骨格を有する細胞及びその使用

Country Status (10)

Country Link
US (2) US20250228943A1 (enExample)
EP (1) EP4504914A4 (enExample)
JP (2) JP7701453B2 (enExample)
KR (1) KR20250005097A (enExample)
CN (1) CN119256075A (enExample)
AU (1) AU2023249802A1 (enExample)
CA (1) CA3247423A1 (enExample)
IL (1) IL316101A (enExample)
MX (1) MX2024008227A (enExample)
WO (1) WO2023196994A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022098914A1 (en) * 2020-11-04 2022-05-12 Fate Therapeutics, Inc. Engineered ipsc and persistent immune effector cells
JP2024539013A (ja) * 2021-10-20 2024-10-28 フェイト セラピューティクス，インコーポレイティド 固形腫瘍における同種異系養子細胞療法のためのエフェクター細胞及びその使用
IL312565A (en) * 2021-11-08 2024-07-01 Fate Therapeutics Inc Engineered effector cells for trafficking of allogeneic cell therapies in solid tumors
WO2025101809A1 (en) * 2023-11-08 2025-05-15 Fate Therapeutics, Inc. Ipsc-derived t cells for solid tumor treatment

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021071962A1 (en) 2019-10-07 2021-04-15 Fate Therapeutics, Inc. Enhanced chimeric antigen receptor for immune effector cell engineering and use thereof
WO2021077117A1 (en) 2019-10-17 2021-04-22 Fate Therapeutics, Inc. Enhanced chimeric antigen receptor for immune effector cell engineering and use thereof
WO2022098914A1 (en) 2020-11-04 2022-05-12 Fate Therapeutics, Inc. Engineered ipsc and persistent immune effector cells
WO2022098925A1 (en) 2020-11-04 2022-05-12 Fate Therapeutics, Inc. Engineered ipsc and immune effector cells for heterogenous tumor control
WO2022114163A1 (ja) 2020-11-30 2022-06-02 小野薬品工業株式会社 Ｈｅｒ２標的化剤
WO2023196982A1 (en) 2022-04-08 2023-10-12 Fate Therapeutics, Inc. Chimeric antigen receptor for tumor targeting

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
GB9710807D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
US6140081A (en) 1998-10-16 2000-10-31 The Scripps Research Institute Zinc finger binding domains for GNN
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
JP2002060786A (ja) 2000-08-23 2002-02-26 Kao Corp 硬質表面用殺菌防汚剤
US20040224385A1 (en) 2001-08-20 2004-11-11 Barbas Carlos F Zinc finger binding domains for cnn
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US7972854B2 (en) 2004-02-05 2011-07-05 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
AU2005250408B2 (en) 2004-05-27 2010-09-23 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses therefor
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
PT2816112T (pt) 2009-12-10 2018-11-20 Univ Iowa State Res Found Inc Modificação do adn modificada pelo efector tal
WO2011159726A2 (en) 2010-06-14 2011-12-22 The Scripps Research Institute Reprogramming of cells to a new fate
MX2014001222A (es) 2011-07-29 2014-09-15 Univ Pennsylvania Receptores coestimuladores de cambio.
EP2814846B1 (en) 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
SG10201806573TA (en) 2012-05-25 2018-09-27 Cellectis Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
IL305629A (en) 2013-02-15 2023-11-01 Univ California Chimeric antigen receptor and methods of using it
US9932607B2 (en) 2013-11-15 2018-04-03 The Board Of Trustees Of The Leland Stanford Junior University Site-specific integration of transgenes into human cells
EP3104866A4 (en) 2014-02-14 2017-08-02 Bellicum Pharmaceuticals, Inc. Methods for activating t cells using an inducible chimeric polypeptide
DK3105335T3 (da) 2014-02-14 2020-01-13 Univ Texas Kimære antigenreceptorer og fremgangsmåder til fremstilling heraf
CN120536341A (zh) 2014-03-04 2025-08-26 菲特治疗公司 改良的重编程方法和细胞培养平台
US20170158749A1 (en) 2014-04-23 2017-06-08 Board Of Regents, The University Of Texas System Chimeric antigen receptors (car) and methods for making and using the same
AU2015312117A1 (en) 2014-09-02 2017-03-02 Bellicum Pharmaceuticals, Inc. Costimulation of chimeric antigen receptors by Myd88 and CD40 polypeptides
WO2016126608A1 (en) * 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
WO2016149665A1 (en) 2015-03-18 2016-09-22 Baylor College Of Medicine Her2/erbb2 chimeric antigen receptor
CN117737124A (zh) 2015-10-16 2024-03-22 菲特治疗公司 用于诱导和维护基态多能性的平台
CN122146606A (zh) 2015-11-04 2026-06-05 菲特治疗公司 用于诱导造血细胞分化的方法和组合物
ES2909973T3 (es) * 2015-11-04 2022-05-10 Hope City Receptores quiméricos para el antígeno que se dirigen a HER2
CA3007473A1 (en) 2015-12-14 2017-06-22 Bellicum Pharmaceuticals, Inc. Dual controls for therapeutic cell activation or elimination
JP7653759B2 (ja) 2016-01-20 2025-03-31 フェイト セラピューティクス，インコーポレイテッド 養子免疫療法における免疫細胞調節のための組成物および方法
US12247226B2 (en) 2017-10-11 2025-03-11 Fate Therapeutics, Inc. Cellular reprogramming using temporal and transient plasmid vector expression system
US11649294B2 (en) 2017-11-14 2023-05-16 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
CN111556892A (zh) * 2017-12-08 2020-08-18 菲特治疗公司 使用增强的iPSC衍生的效应细胞的免疫疗法
BR112020011017A2 (pt) * 2017-12-22 2020-11-17 Fate Therapeutics, Inc. células efetoras imunes intensificadas e uso das mesmas
SG10201801219VA (en) 2018-02-13 2019-09-27 Agency Science Tech & Res Anti-HER2 Antibodies
AU2019243315A1 (en) * 2018-03-29 2020-09-24 Fate Therapeutics, Inc. Engineered immune effector cells and use thereof
EP3824075A4 (en) * 2018-07-17 2022-04-20 The Regents of The University of California CHIMERA ANTIGEN RECEPTOR T-CELLS DERIVED FROM IMMUNOMANIPULATED PLURIPOTENTS STEM CELLS
EP3848387A4 (en) * 2018-09-05 2022-06-22 Kong, Seogkyoung CHIMERIC ANTIGEN RECEPTOR FOR SOLID TUMOR AND T-CELLS EXPRESSING A CHIMERIC ANTIGEN RECEPTOR
WO2020092057A1 (en) * 2018-10-30 2020-05-07 Yale University Compositions and methods for rapid and modular generation of chimeric antigen receptor t cells
JP2022525928A (ja) * 2019-03-21 2022-05-20 ガミダ セル リミテッド 併用療法における移植に適したｎｋ細胞画分の増殖及び増殖ｎｋ細胞画分の使用
EP3941947A4 (en) 2019-03-22 2022-12-14 Olivia Newton-John Cancer Research Institute ANTI-HER2 BINDING MOLECULES
WO2020197319A1 (ko) * 2019-03-28 2020-10-01 한국생명공학연구원 면역세포의 제조방법 및 그의 용도
KR20220035190A (ko) * 2019-07-17 2022-03-21 페이트 세러퓨틱스, 인코포레이티드 면역 효과기 세포 조작 및 이의 용도
US20220378831A1 (en) * 2019-09-25 2022-12-01 Fate Therapeutics, Inc. Multi-targeting effector cells and use thereof
JP7879804B2 (ja) * 2019-12-06 2026-06-24 フェイト セラピューティクス，インコーポレイテッド 小化合物を使用するｉＰＳＣ由来エフェクター免疫細胞の増強
CN115485293A (zh) 2020-01-23 2022-12-16 埃克苏马生物技术公司 用于her2的嵌合抗原受体和其使用方法
US11230699B2 (en) * 2020-01-28 2022-01-25 Immunitybio, Inc. Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors
WO2021235894A1 (en) 2020-05-22 2021-11-25 Green Cross Lab Cell Corporation Anti-HER2 Antibody or Antigen-binding Fragment thereof, and Chimeric Antigen Receptor Comprising Same
CN112391414A (zh) 2020-11-17 2021-02-23 中国医学科学院基础医学研究所 一种靶向her2的car-t表达载体及其构建和应用

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021071962A1 (en) 2019-10-07 2021-04-15 Fate Therapeutics, Inc. Enhanced chimeric antigen receptor for immune effector cell engineering and use thereof
WO2021077117A1 (en) 2019-10-17 2021-04-22 Fate Therapeutics, Inc. Enhanced chimeric antigen receptor for immune effector cell engineering and use thereof
WO2022098914A1 (en) 2020-11-04 2022-05-12 Fate Therapeutics, Inc. Engineered ipsc and persistent immune effector cells
WO2022098925A1 (en) 2020-11-04 2022-05-12 Fate Therapeutics, Inc. Engineered ipsc and immune effector cells for heterogenous tumor control
WO2022114163A1 (ja) 2020-11-30 2022-06-02 小野薬品工業株式会社 Ｈｅｒ２標的化剤
WO2023196982A1 (en) 2022-04-08 2023-10-12 Fate Therapeutics, Inc. Chimeric antigen receptor for tumor targeting

Also Published As

Publication number Publication date
CA3247423A1 (en) 2023-10-12
JP2025105605A (ja) 2025-07-10
US20250228943A1 (en) 2025-07-17
US12203098B2 (en) 2025-01-21
EP4504914A4 (en) 2026-04-29
AU2023249802A1 (en) 2024-10-24
KR20250005097A (ko) 2025-01-09
JP2024515920A (ja) 2024-04-11
US20230357716A1 (en) 2023-11-09
WO2023196994A1 (en) 2023-10-12
IL316101A (en) 2024-12-01
CN119256075A (zh) 2025-01-03
MX2024008227A (es) 2024-07-19
EP4504914A1 (en) 2025-02-12

Similar Documents

Publication Publication Date Title
JP7467339B2 (ja) 強化された免疫エフェクター細胞およびその使用
US12203098B2 (en) Cells having solid tumor targeting backbone and use thereof
JP2023548467A (ja) 操作されたｉＰＳＣ及び持続性免疫エフェクター細胞
JP2025522824A (ja) 養子細胞療法におけるエフェクター細胞の耐久性及び有効性の増強
JP2024526237A (ja) 同種異系養子細胞療法のための保護されたエフェクター細胞及びその使用
US20250339532A1 (en) Stealth strategy engaging immune recognition pathways for use in allogeneic cell therapies
US20250018034A1 (en) Engineered effector cells and methods of enhancing ubiquitous targeting of solid tumors
US20250009882A1 (en) Engineered effector cells for trafficking of allogeneic cell therapies in solid tumors
TW202417618A (zh) 具有實體腫瘤靶向主鏈之細胞及其用途
HK40117639A (en) Cells having solid tumor targeting backbone and use thereof
KR20260049588A (ko) 이펙터 세포의 분화 및 기능을 촉진하는 고형 종양 표적화 골격
WO2026102183A1 (en) Effector cells having enhanced target cell recognition
JP2024539013A (ja) 固形腫瘍における同種異系養子細胞療法のためのエフェクター細胞及びその使用
HK40118439A (en) Stealth strategy engaging immune recognition pathways for use in allogeneic cell therapies
HK40111237A (en) Engineered effector cells for trafficking of allogeneic cell therapies in solid tumors
CN118318034A (zh) 用于实体瘤的运输同种异体细胞疗法的工程改造的效应细胞
HK40113362A (en) Engineered effector cells and methods of enhancing ubiquitous targeting of solid tumors
CN118369107A (zh) 工程改造的效应细胞和增强对实体瘤的普遍靶向的方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230821

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230821

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20230821

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240507

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20240806

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241029

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250228

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250520

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250619

R150 Certificate of patent or registration of utility model

Ref document number: 7701453

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150